All In Biotech

Drug Trial Radar · NCT07711470

Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC

A Multicenter, Prospective Phase II Trial Evaluating Induction Chemotherapy Plus Sugemalimab Followed by Sequential Radiotherapy and Response-Guided Surgery or Organ Preservation in Resectable Esophageal Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 31, 2028

Study completion Jul 31, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC). Participants will receive two cycles of induction chemoimmunotherapy with sugemalimab, nab-paclitaxel, and cisplatin. Patients who achieve a major clinical response will receive definitive radiotherapy plus sugemalimab followed by maintenance sugemalimab, while non-major responders will undergo surgery-based treatment strategies. The study aims to evaluate the efficacy and safety of this tailored treatment approach, with the primary endpoint being 2-year progression-free survival. Secondary and exploratory objectives include survival outcomes, quality of life, nutritional status.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

  • Sugemalimab and ChemotherapyDrug

    Sugemalimab 1200 mg administered intravenously every 3 weeks as induction, and maintenance immunotherapy.

  • Nab-paclitaxelDrug

    125 mg/m² administered intravenously on Days 1 and 8 every 3 weeks during induction therapy.

  • CisplatinDrug

    75 mg/m² administered intravenously on Day 1 every 3 weeks during induction therapy.

  • Radiation TherapyRadiation

    IMRT: PTV 41.4 Gy/23f,PGTV 49.45 Gy/23f

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-year PFS rateTime frame: Up to 2 years after initiation of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.